-
公开(公告)号:US20210330628A1
公开(公告)日:2021-10-28
申请号:US17316861
申请日:2021-05-11
Applicant: Almirall, S.A.
Inventor: Maria PLANELLS JIMENEZ , Begoña DUARTE LOPEZ , Pere GUIRO COLL
IPC: A61K31/225 , A61K9/16 , A61K9/28 , A61K9/20
Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
-
公开(公告)号:US20200255478A1
公开(公告)日:2020-08-13
申请号:US16636679
申请日:2018-08-08
Applicant: Almirall, S.A.
Inventor: Carlos PUIG DURAN , Fernando ALBERICIO PALOMERA , Miriam GONGORA BENITEZ , Marta PARADIS BAS , Laia MIRET CASALS , Ivan RAMOS TOMILLERO , Stephen FIACCO , Andrew DAVIS , Stefan GESCHWINDNER , Omar BRUN CUBERO , Carlos HERAS PANIAGUA , Nuria TRALLERO CANELA
IPC: C07K7/64
Abstract: The invention relates to peptidic compounds, which peptidic compounds are compounds of formula (I)′, or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof: wherein R1; R2; s; t; u; Aa78 and G1 are as defined herein.The peptidic compounds are useful in activating the Nrf2 pathway.
-
公开(公告)号:US20190231788A1
公开(公告)日:2019-08-01
申请号:US16309814
申请日:2017-06-15
Applicant: Almirall, S.A.
Inventor: Nuria Godessart Marina , Gema Tarrason Encuentra
IPC: A61K31/5377 , A61K31/7048 , A61K31/4164 , A61K31/4985 , A61K9/00 , A61K9/06 , A61K47/44 , A61P17/00
CPC classification number: A61K31/5377 , A61K9/0014 , A61K9/06 , A61K31/4164 , A61K31/4985 , A61K31/7048 , A61K47/10 , A61K47/44 , A61P17/00 , A61K2300/00
Abstract: The present invention relates to combinations comprising timolol and a compound useful for the treatment of rosacea selected from ivermectin, metronidazole and praziquantel and to the use of these combinations in the topical treatment of rosacea.
-
公开(公告)号:US10085974B2
公开(公告)日:2018-10-02
申请号:US13692032
申请日:2012-12-03
Applicant: Almirall, S.A.
Inventor: Rosa Lamarca Casado , Gonzalo De Miquel Serra
IPC: A61K31/439 , A61K45/06 , A61K9/00 , A61K31/167 , A61K31/46
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
-
公开(公告)号:US20180244626A1
公开(公告)日:2018-08-30
申请号:US15559120
申请日:2016-03-22
Applicant: ALMIRALL, S.A.
Inventor: Laia SOLE FEU , Silvia FONQUERNA POU
IPC: C07D231/56 , A61K31/416 , A61K45/06 , C07D401/04 , A61K31/454 , A61K31/4545 , A61K31/4439 , C07D471/04 , A61K31/437 , C07D487/04 , A61K31/4985 , A61K31/5377 , C07D405/10
CPC classification number: C07D231/56 , A61K31/416 , A61K31/4162 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D405/10 , C07D471/04 , C07D487/04
Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav 1.7, to compositions containing said derivatives and processes for their preparation,
-
公开(公告)号:US20180162856A1
公开(公告)日:2018-06-14
申请号:US15735235
申请日:2016-06-10
Applicant: ALMIRALL, S.A.
Inventor: Cristina ESTEVE TRIAS , Joan TALTAVULL MOLL , Jacob GONZALES RODRIGUEZ , Bernat VIDAL JUAN
IPC: C07D471/04 , C07D239/24
Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).
-
公开(公告)号:US09907807B2
公开(公告)日:2018-03-06
申请号:US14883898
申请日:2015-10-15
Applicant: Almirall, S.A.
Inventor: Fritjof Evers , Henning Mallwitz , Ricarda Wessel , Christoph Willers
Abstract: Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
-
8.
公开(公告)号:US20180015097A1
公开(公告)日:2018-01-18
申请号:US15668817
申请日:2017-08-04
Applicant: ALMIRALL,S.A
Inventor: Jose AIGUADE BOSCH , Silvia Gual Roig , Maria Prat Quinones , Carlos Puig Duran
IPC: A61K31/538 , A61K31/4178 , C07D413/14 , C07D413/12 , C07D409/14 , C07D409/12 , C07D403/12 , C07D401/12 , C07D263/58 , A61K45/06 , A61K31/4709 , A61K31/428 , A61K31/423 , A61K31/4184 , C07D417/12 , C07D417/14
CPC classification number: A61K31/538 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4709 , A61K45/06 , C07D263/58 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
-
公开(公告)号:US20160331733A1
公开(公告)日:2016-11-17
申请号:US15218391
申请日:2016-07-25
Applicant: Almirall, S.A.
Inventor: Diana JARRETA FERNANDEZ , Maria Esther GARCIA GIL
IPC: A61K31/439 , A61K45/06 , A61K9/00
CPC classification number: A61K31/439 , A61K9/0075 , A61K45/06 , A61K2300/00
Abstract: The present disclosure provides aclidinium or any of its stereoisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.
Abstract translation: 本公开内容提供了吖啶鎓或其任何立体异构体或其立体异构体或其药学上可接受的盐或溶剂合物的混合物,用于改善呼吸患者的睡眠质量。
-
公开(公告)号:US20150246026A1
公开(公告)日:2015-09-03
申请号:US14712866
申请日:2015-05-14
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K9/00 , A61K31/56 , A61K47/26 , A61K45/06
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: A compound according to formula (I) wherein z© is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, —OR4, —SR4, —NR4R5, —NHCOR4, —CONR4R5, —CN, —NO2, —COOR4 or —CF3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R1 and R2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a —CH2—, —CH═CR6, —CR6═CH—, —CR6122—, —CO—, —O—, —S—, —S(O)—, SO2 or NR6— group, wherein R6 and R2 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R6 and 122 together form an alicyclic ring; m is an integer from 0 to 8; provided that when m=0, A is not —CH2—; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2,3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula (i) or (ii), wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represents formulae (a), (b), (c), (d) and wherein R11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, —CH2—, —CH2—CH2, —O—, —O—CH2—, —S—, —S—CH2— or —CH═CH—, and when (i) or (ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, which shows high affinity for muscarinic M3 receptors (Hm3).
-
-
-
-
-
-
-
-
-